A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials
暂无分享,去创建一个
Masahiro Takeuchi | Hajime Uno | Angel M Cronin | H. Uno | M. Takeuchi | A. Cronin | Miki Horiguchi | M. Horiguchi
[1] Hajime Uno,et al. A versatile test for equality of two survival functions based on weighted differences of Kaplan–Meier curves , 2015, Statistics in medicine.
[2] Z. Ying,et al. A resampling method based on pivotal estimating functions , 1994 .
[3] G. Neuhaus,et al. Conditional Rank Tests for the Two-Sample Problem Under Random Censorship , 1993 .
[4] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[5] R. Tarone,et al. On the distribution of the maximum of the longrank statistic and the modified Wilcoxon statistic , 1981 .
[6] Jon A. Wellner,et al. Weak Convergence and Empirical Processes: With Applications to Statistics , 1996 .
[7] Patrick Royston,et al. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.
[8] R. A’Hern. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S G Self,et al. An adaptive weighted log-rank test with application to cancer prevention and screening trials. , 1991, Biometrics.
[10] M. Piccart,et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G Heimann,et al. Permutational distribution of the log-rank statistic under random censorship with applications to carcinogenicity assays. , 1998, Biometrics.
[12] M S Pepe,et al. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. , 1989, Biometrics.
[13] R. Prentice. Linear rank tests with right censored data , 1978 .
[14] N. Lazar,et al. The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .
[15] R. Chappell,et al. Describing Differences in Survival Curves. , 2016, JAMA oncology.
[16] Song Yang,et al. Improved Logrank‐Type Tests for Survival Data Using Adaptive Weights , 2010, Biometrics.
[17] Z. Ying,et al. Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .
[18] Patrick Royston,et al. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated , 2016, BMC Medical Research Methodology.
[19] Lihui Zhao,et al. On the restricted mean survival time curve in survival analysis , 2016, Biometrics.
[20] L. Tian,et al. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations , 2018, Biometrics.
[21] H. Uno,et al. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. , 2015, Annals of internal medicine.
[22] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[23] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[24] P. Royston,et al. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.
[25] D. Zucker,et al. Weighted log rank type statistics for comparing survival curves when there is a time lag in the effectiveness of treatment , 1990 .
[26] P. Royston,et al. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards , 2017, British Medical Journal.
[27] Michael R. Kosorok,et al. The Versatility of Function-Indexed Weighted Log-Rank Statistics , 1999 .
[28] J O'Quigley,et al. Estimating average regression effect under non-proportional hazards. , 2000, Biostatistics.
[29] L. Trinquart,et al. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Buyse,et al. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. , 2016, JAMA oncology.
[31] Yoshiaki Uyama,et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Chauvel,et al. Tests for comparing estimated survival functions , 2014 .
[33] Jae Won Lee,et al. SOME VERSATILE TESTS BASED ON THE SIMULTANEOUS USE OF WEIGHTED LOG-RANK STATISTICS , 1996 .
[34] Joseph L. Gastwirth,et al. The Use of Maximin Efficiency Robust Tests in Combining Contingency Tables and Survival Analysis , 1985 .